Please check your internet connection and try again.
# Meftal Spas
## Overview
Meftal Spas is a combination product containing mefenamic acid (a nonsteroidal anti-inflammatory drug, NSAID) and hyoscine butylbromide (an anticholinergic antispasmodic). Mefenamic acid reduces inflammation and pain, while hyoscine butylbromide relaxes smooth muscle in the gastrointestinal tract, relieving spasms.
## Primary Indications
* Pain associated with smooth muscle spasms, particularly in the gastrointestinal tract, biliary, and urinary systems.
* Dysmenorrhea.
## Adult Dosing
* **Typical Dose:** 1 tablet (250 mg mefenamic acid / 10 mg hyoscine butylbromide) three times daily as needed for pain.
* **Maximum Dose:** Not to exceed 4 tablets per day.
## Pediatric Dosing
* Dosing in pediatric populations is not well-established for this specific combination product. Use with caution and consider individual components if necessary. Mefenamic acid pediatric dosing is typically based on weight. Hyoscine butylbromide dosing in children is also weight-based.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid is renally excreted. Consider dose reduction or discontinuation in severe impairment.
* **Hepatic Impairment:** Use with caution. Monitor liver function.
* **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding, renal toxicity, and cardiovascular events. Use at the lowest effective dose for the shortest duration.
## Contraindications
* Hypersensitivity to mefenamic acid, hyoscine butylbromide, or other NSAIDs.
* Active gastrointestinal ulceration or inflammation.
* History of NSAID-induced ulceration or bleeding.
* Severe renal or hepatic impairment.
* Myasthenia gravis.
* Tachyarrhythmias.
* Angle-closure glaucoma.
* Prostatic hypertrophy with urinary retention.
* Gastrointestinal obstruction or paralytic ileus.
* Children under 12 years of age (due to mefenamic acid).
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, dyspepsia, constipation, dry mouth, blurred vision, dizziness, headache.
* **Serious:**
* **Gastrointestinal:** GI bleeding, ulceration, perforation, exacerbation of inflammatory bowel disease.
* **Cardiovascular:** Increased risk of thrombotic events (MI, stroke) with NSAID use.
* **Renal:** Renal papillary necrosis, interstitial nephritis, renal failure.
* **Hepatic:** Hepatitis, jaundice.
* **Ophthalmic:** Dilated pupils, photophobia, increased intraocular pressure (due to hyoscine).
* **Other:** Allergic reactions, bronchospasm, anaphylaxis.
## Key Drug Interactions
* **NSAIDs:** Increased risk of GI toxicity with concurrent NSAIDs.
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Diuretics:** Reduced diuretic effect and increased risk of renal toxicity.
* **ACE inhibitors/ARBs:** Increased risk of renal impairment.
* **Lithium:** Increased lithium levels.
* **Methotrexate:** Increased methotrexate toxicity.
* **Other Anticholinergics:** Additive anticholinergic effects (e.g., with tricyclic antidepressants, antihistamines).
## Monitoring
* **Gastrointestinal:** Monitor for signs and symptoms of GI bleeding (e.g., melena, hematemesis).
* **Renal Function:** Monitor serum creatinine and BUN, especially in patients with pre-existing renal disease or those at risk.
* **Hepatic Function:** Monitor liver enzymes, especially with long-term use or in patients with hepatic impairment.
* **Blood Pressure:** Monitor blood pressure, as NSAIDs can cause hypertension.
## Clinical Pearls
* Use the lowest effective dose for the shortest duration necessary to minimize risks.
* Consider co-prescription of a proton pump inhibitor (PPI) or misoprostol for patients at high risk of GI complications.
* Advise patients to avoid alcohol due to increased risk of GI irritation and bleeding.
* Inform patients about potential anticholinergic side effects such as dry mouth, blurred vision, and urinary retention.
This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and relevant clinical guidelines. Always verify current prescribing information.
